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Abstract
Background: Erythropoietin receptors have been identified in human skeletal muscle tissue, but downstream signal
transduction has not been investigated. We therefore studied in vivo effects of systemic erythropoietin exposure in human
skeletal muscle.
Methodology/Principal Findings: The protocols involved 1) acute effects of a single bolus injection of erythropoietin
followed by consecutive muscle biopsies for 1–10 hours, and 2) a separate study with prolonged administration for 16 days
with biopsies obtained before and after. The presence of erythropoietin receptors in muscle tissue as well as activation of
Epo signalling pathways (STAT5, MAPK, Akt, IKK) were analysed by western blotting. Changes in muscle protein profiles after
prolonged erythropoietin treatment were evaluated by 2D gel-electrophoresis and mass spectrometry. The presence of the
erythropoietin receptor in skeletal muscle was confirmed, by the M20 but not the C20 antibody. However, no significant
changes in phosphorylation of the Epo-R, STAT5, MAPK, Akt, Lyn, IKK, and p70S6K after erythropoietin administration were
detected. The level of 8 protein spots were significantly altered after 16 days of rHuEpo treatment; one isoform of myosin
light chain 3 and one of desmin/actin were decreased, while three isoforms of creatine kinase and two of glyceraldehyd-3-
phosphate dehydrogenase were increased.
Conclusions/Significance: Acute exposure to recombinant human erythropoietin is not associated by detectable activation
of the Epo-R or downstream signalling targets in human skeletal muscle in the resting situation, whereas more prolonged
exposure induces significant changes in the skeletal muscle proteome. The absence of functional Epo receptor activity in
human skeletal muscle indicates that the long-term effects are indirect and probably related to an increased oxidative
capacity in this tissue.
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Introduction
Erythropoietin (Epo) is the main regulator of erythropoiesis [1].
The primary site for Epo production is the kidney, where it is
produced in a hypoxia-dependent manner. However, small
amounts are also produced in the liver and brain [2]. Epo binds
to a specific receptor (Epo-R), that belongs to the cytokine receptor
superfamily and activates the JAK/STAT, PI3-kinase, NF-kB/
IKK, and/or the Ras/MAP kinase pathways [1,3,4]. Through
these pathways Epo exerts anti-apoptotic effects during the later
stages of erythroid progenitor cell development in the bone
marrow, by decreasing the rate of cell death and hence inducing
these cells to proliferate and mature [1].
Epo-Rs have been identified on a variety of different cell types
including renal, endothelial, vascular smooth muscle, gastric
mucosal, and Leydig cells, as well as cells of the placenta, certain
cancer cells, cardiomyocytes, astrocytes, and neurons [2,5–10].
The main biological function of Epo in these cells is to facilitate
proliferation, angiogenesis, and cytoprotection [2,9,11]. Further-
more, Epo-Rs are expressed in vitro on murine myoblasts and
primary satellite cells, both of which exhibit a proliferative
response to Epo stimulation [12]. Recently, the Epo-R was also
discovered on human skeletal muscle cells [13,14]; however, the
physiological role of Epo in this tissue remains uncertain [15].
Several studies have investigated changes in mRNA levels of
pertinent proteins and structural changes in muscle after
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recombinant human Epo (rHuEpo) administration with conflicting
results [13,16,17]. Thus, even though the Epo-R has been
identified in human skeletal muscle tissue, its role remains
incompletely understood.
Investigations of the activation of the signalling cascades related
to the Epo-R, could give insight into the physiological role of the
Epo-R in skeletal muscle tissue. To our knowledge, no previous
studies have analysed Epo induced intracellular signalling
pathways in human skeletal muscle in vivo. We therefore
investigated the activation of a variety of molecules involved in
signalling from the Epo-R (STAT5, p38-MAPK, Akt, Lyn, IKK,
and p70S6K) and gene transcripts (SOCS-3) in response to acute
stimulation of the Epo-R by rHuEpo. Lyn is a non-receptor
protein tyrosine kinase, which acts as a docking protein that is pre-
associated with the Epo-R and bind to the Epo-R and Jak2 [18].
Lyn mediates the phosphorylation of the Epo-R and activation of
the signalling cascades STAT5, PI3-K and NF-kB [18–20]. The
main signalling pathways through which Epo signals are STAT5,
MAPK, PI3-K/akt, and NF-kB/IKK [1,2,4], each of these
pathways were investigated here. Epo-R signalling is reversibly
inhibited by SOCS-3, wherefore its gene transcript was measured
[21]. Furthermore, IGF-I expression was measured to rule out any
GH induced activation of the signalling cascades of interest.
Moreover, we also identified changes in human muscle proteome
following prolonged Epo administration. In the current study two
different doses of rHuEpo was investigated. In study A, a dose of
15,000 IU was administrated, which is comparable to the doses
used to treat patients with end-stage renal disease. In study B, an
even higher dose (400 IU/kg,32,000 IU per subject), comparable
to the dose employed to treat patients with stroke, was used.
Based on the presence of the Epo-R in skeletal muscle tissue, we
hypothesized that rHuEpo treatment would lead to activation of
STAT5, p38-MAPK, Akt, Lyn, IKK, and p70S6K downstream of
the Epo-R, which would lead to changes in the skeletal muscle
protein content.
Methods
Subjects and ethical approval
Acute studies (A and B). In study A, eight healthy male
subjects (2767 yr, 18064 cm, 8367 kg, mean 6 SE) were
included, all of whom provided a written informed consent to
participate in the study, which was approved by the local human
ethical committee of Copenhagen and Frederiksberg (KF 01-269-
637), in adherence to the declaration of Helsinki. Data related to
changes in mRNA content among these subjects have previously
been published [13].
In study B, ten healthy young men (2360.7 yr, 18062 cm,
76.662.2 kg, mean 6 SE) were enrolled. All subjects provided a
written informed consent to participate in the study, which was
approved by the local human ethical committee of Central Denmark
Region (M-2008-0016), in adherence to the declaration of Helsinki.
Prolonged study (C). Eight healthy male volunteers were
included (2564 yr, 18366 cm, 7967 kg, mean 6 SE). All
subjects provided a written informed consent to participate in
the study, which was approved by the local human ethical
committee of Copenhagen and Frederiksberg, Denmark (KF 01
269 637), in adherence to the declaration of Helsinki. Results
describing basic serum hematological changes after Epo
administration to these subjects have already been published [22].
Experimental design
Acute studies (A and B). Study A was performed in a
double-blind, randomised, placebo-controlled, crossover design.
The subjects arrived fasting (from 10 pm the day before) at the lab
and were served a light standardized breakfast adjusted for body
weight and activity level; a blood sample and the first biopsy (pre)
were collected 2 hours later after resting in the supine position.
The biopsies were collected from m. vastus lateralis and taken
before (Pre) and 2 h, 4 h, 6 h, and 10 h post I.V. administration of
either rHuEpo (15.000 IU, NeoRecormon, Roche) or placebo
(saline). Biopsies were immediately frozen in liquid nitrogen, and
stored at 280uC until further analysis. After the 6 h biopsy, the
subjects were served a standardized meal (same on both
experimental days). Blood samples were taken at the same time-
points as the biopsies, centrifuged at 25006g for 15 minutes, and
stored at 220uC until analysed. Biopsies from before injection of
rHuEpo/placebo and 2 h, 4 h, and 6 h post, were used for protein
extraction and western blotting. The 10 h post biopsy was used for
mRNA quantification.
Study B had a single-blind, randomised, placebo-controlled,
cross-over design with a 14-day wash-out period in-between.
Before enrolment, the subjects were examined by a medical doctor
to ensure general health and standard blood analysis (haematol-
ogy, organ markers (LDH, ALAT, bilirubin and basic phospha-
tase), and electrolyte balance) was performed. The subjects were
examined on two occasions: 1) i.v. treatment with 400 IU/kg
Eprex (Epoietin alpha) or 2) placebo (saline), both administered at
t = 0 min. The subjects arrived fasting (from 10pm the evening
before, water allowed) at the lab in the morning. Muscle biopsies
were collected from m. vastus lateralis and taken one hour
(t = 60 min) after Epo/saline administration. The biopsies were
immediately frozen in liquid nitrogen and stored at 280uC until
further analysis. Serum and plasma were collected 4 h post
treatment, centrifuged and stored at 220uC.
Prolonged study (C). Muscle biopsies from m. vastus
lateralis were collected approximately 1 week before the first
Epo injection. Epo (epoetin b; NeoRecormon, Roche, Mannheim,
Germany) was injected every second day (day 0, 2, 4, 6, 8, 10, 12,
14) subcutaneously at a dose of 5000 IU. A second muscle biopsy
was collected on day 16. Muscle biopsies were frozen immediately
in liquid nitrogen and stored at 280uC until further analysis was
performed.
Analysis in plasma/serum
Study A. Plasma concentrations of insulin and GH were
measured in duplicates by ELISA (Electra-Box diagnostica,
Tyreso¨, Sweden; IBL-Hamburg, Germany; BioSource, Nivelles,
Belgium), as previously described [13].
Study B. Insulin and GH were analysed by commercial time-
resolved immunefluorometric assays (TR-IFMA; AutoDELFIA,
PerkinElmer, Turku, Finland) (Insulin: intra-assay CV 3.4% and
inter-assay CV 3.8%, GH: intra-assay CV,8% and inter-assay
CV,10%).
Cell signaling analysis
Protein purification. Proteins were purified from the
biopsies (30–50 mg) by homogenization on ice with a polytron
in homogenization buffer (20 mM Tris HCL, 50 mM NaF, 5 mM
tetrasodium pyrophosphate, 270 mM sucrose, 1% (v/v) Triton-
X100, 1 mM EDTA, 1 mM EGTA, 10 mM glycerolphosphat,
2 mM DTT, 50 mg/ml soybean trypsin inhibitor, 4 mg/ml
leupeptin, 100 mM benzamidine, and 500 mM PMSF, pH=7.4).
The homogenate was left on ice for 30 min with occasional
vortexing, before being centrifuged at 14000 g at 4uC for 20 min.
The supernatant was collected, frozen in liquid nitrogen, and
stored at 280uC until analyses were performed. Protein
concentration was determined by the Bradford assay (Protein
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Assay, #500-0006, Bio Rad laboratories Inc, CA, USA. Albumin
standard, Thermo Scientific, IL, USA. Victor 3, 1420 multilabel
counter, Perkin Elmer).
Western blot analysis. The protein fraction was analysed
for phosphorylation of Epo-R, Lyn, STAT5, Akt, p70S6-kinase,
MAPK and for total Epo-R. Primary antibodies were as follows:
anti-phospho-Epo-R(Tyr456) (Santa Cruz, #sc20236), anti-Lyn
(Cell signalling, #2732), anti-phospho-Lyn(Tyr507) (Cell signall-
ing, #2731), anti-STAT5 (Cell signalling, #9310), anti-phospho-
STAT5(Tyr694) (Cell signalling, #9351), anti-Akt/PKB (Cell
signalling, #9272), anti-phospho-Akt/PKB(Ser473) (Cell signall-
ing, #9271), anti-phospho-Akt/PKB(Thr308) (Cell signalling,
#9275), anti-p70S6 kinase (Cell signalling, #9202), anti-
phospho-p70S6 kinase(Thr389) (Cell signalling, #9205), anti-
p38-MAP kinase (Cell signalling, #9212), anti-phospho-p38-MAP
kinase (Thr180/Thr182) (Cell signalling, #9211), anti-IKKa (Cell
signalling, #2682), anti-phospho-IKKa/b(Ser176/180) (Cell
signalling, #2697), anti-Epo-R (M20) (Santa Cruz, #sc697),
anti-Epo-R (C20) (Santa Cruz, #sc695), and anti-b-actin (Abcam,
#ab8227). Donkey anti-rabbit IgG horseradish peroxidise (HRP)
was used as secondary antibody (Amersham, #NA934). Briefly,
western blotting was performed as follows; 20–30 mg of protein
was loaded onto a 4–12% SDS Criterion Gel (BioRad, Hercules,
CA, USA), followed by electro blotting onto a nitrocellulose or
PVDF membrane. Membranes were blocked with blocking buffer
(5% BSA, 0.01% NaN3 in TBS buffer) before primary antibody
was added overnight at 4uC. Following several washes, the
membrane was incubated with the secondary antibody for 60 min
at room temperature. The protein of interest was detected by a
chemiluminescence detection system (Super Signal West Dura
Extended duration substrate, Pierce cat.no. 34075) and visualized
using an image system (UPV BioImaging systems). The PVDF
membranes were stripped after visualization of the phospho-
antibodies and re-incubated with the total antibodies. Membranes
were stripped (62,5 mM Tris HCL ph 6.8, 2% SDS, 73,75 ml
dH2O) for 1 h at 55uC.
Real-time PCR. Skeletal muscle (30 mg) samples were
homogenized in TriZol reagent (Gibco BRL, Life Technologies,
Roskilde, Denmark) added DNase and proteinaseK and total
RNA was extracted following the manufacture’s protocol. RNA
was quantified by measuring absorbance at 260 and 280 nm using
a NanoDrop 8000 (NanoDrop products, Bancroft, DE USA), and
the inclusion criteria was a ratio $1.8. Finally, the integrity of the
RNA was checked by visual inspection of the two ribosomal
RNAs, 18 S and 28 S, on an agarose gel.
For real-time reverse transcriptase PCR, complementary DNA
was constructed using random hexamer primers as described by
the manufacturer (Verso cDNA kit, Abgene, Epsom, UK). Then
KAPA SYBR FAST qPCR mastermix (Kapa Biosystems, Inc.
Woburn, MA, USA) and the following primer pairs were added:
SOCS3 primers: 59-GCCCTTTGCGCCCTTT-39 and 59-
CGGCCACCTGGACTCCTATGA-39, IGF-I primers (all four
isoforms): 59-GACAGGGGCTTTATTTCAAC-39 and 59-CTC-
CAGCCTCCTTAGATCAC-39, b-actin: 59-TGTGCCCATC-
TACGAGGGGTA-TGC-39 and 59-GGTACATGGTGGTG-C-
CGCCA-GACA-39. Real-time quantification of genes was per-
formed using an ICycler from Bio-Rad (Bio-Rad Laboratories,
Hercules, CA, USA). cDNA with specific primers amplified in
separate tubes, and the increase in fluorescence was measured in
real time. The threshold cycle was calculated, and the relative gene
expression was calculated as target gene (X0) to b-actin (R0) ratio
in each sample before amplification using X0/R0= kx1/((2*DCt))
essentially as described in the User Bulletin no. 2, 1997, from
Perkin-Elmer. All samples were amplified in duplicate. A similar
set-up was used for negative controls, except that the reverse
transcriptase was omitted and no PCR products were detected
under these conditions.
Proteomics analysis
Sample preparation. Before 2D electrophoresis, the muscle
biopsies were homogenized with a mechanical blender and
sonication in sample buffer (7 M urea, 2 M thiourea, 1% w/v
SB 3–10, 3% w/v CHAPS, 0.25% v/v Bio-lyte 3/10 ampholytes
(Bio-Rad Laboratories Inc., Hercules, CA)) added 1.5% v/v
protease inhibitor cocktail (Sigma, St Louis, MO). The total
protein content of each sample was determined using the Bradford
method. Muscle sample volumes containing 300 mg of protein
were diluted in sample buffer (7 M urea, 2 M thiourea, 1% w/v
SB 3–10, 3% w/v CHAPS, 0.25% v/v Bio-Lyte 3/10 ampholytes
(Bio-Rad Laboratories Inc., Hercules, CA)) containing 1.5% v/v
protease inhibitor cocktail (Sigma, St Louis, MO). Disulfide bonds
were reduced by addition of tributylphosphine and sulfhydryl
groups were alkylated with iodoacetamide.
Two-dimensional gel electrophoresis (2DE). For the first
dimension, diluted and treated samples were loaded onto IPG strips
(isoelectric point (pI) 3–10 linear, Bio-Rad) and passively rehydrated
for two hours at room temperature. Then, strips were placed into a
PROTEAN IEF cell (Bio-Rad) for isoelectric focusing consisting of
12 h of active rehydration at 250 V followed by separation at
4000 V for 60000 V h. The strips were then equilibrated for
45 min in equilibration buffer (0.375 M Tris-HCl pH 8.8, 6 M
urea, 2% w/v SDS, and 20% v/v glycerol) and loaded on 15%
polyacrylamide gels. SDS-PAGE was run in a PROTEAN II XL
cell (Bio-Rad) at 25 mA per gel and 270 V6h. Gels were fixed (40%
ethanol, 2% acetic acid, 0.005% w/v SDS), washed three times (2%
acetic acid, 0.005% w/v SDS), stained using SYPRO Orange
(Molecular Probes, Inc., Eugene, OR), and finally scanned in a
PharosFX Plus Molecular Imager (Bio-Rad) with an excitation
wavelength of 488 nm and emission detected at 605 nm.
Image analysis. Protein spots in the gels were matched using
the image analysis software PDQuest Advanced v. 8.0 (Bio-Rad)
and all matches were confirmed manually. Protein spot intensities
were normalized to the total image density in each gel, which
depended on the total protein content of the sample.
Mass spectrometry (MS). Protein spots displaying signi-
ficant (p,0.05) intensity changes at the time-points studied were
manually excised from the gels and sent to Protea Biosciences Inc.
Morgantown, WV for analysis by mass spectrometry (MS) and
tandem-MS (MS/MS) using matrix assisted laser desorption/
ionization-time of flight (MALDI-TOF) and MALDI-TOF-TOF.
Protein identification. Protein identities obtained by Protea
Biosciences were verified or revised using the MS and MS/MS
data and the online software Mascot. Search parameters included
the following: MS: database: NCBInr; taxonomy: Homo sapiens;
enzyme: trypsin; missed cleavages allowed: 1; fixed modifications:
none or carbamidomethyl (C); protein mass: none; peptide
tolerance: 60.1 to 1.2 Da; mass values: MH+; monoisotopic/
average: monoisotopic. Tandem MS: database: NCBInr; taxo-
nomy: Homo sapiens; enzyme: trypsin; missed cleavages allowed: 1;
fixed modifications: none or carbamidomethyl (C); Quantitation:
none; peptide tolerance: 60.1 to 1.2 Da; MS/MS tolerance: 60.1
to 0.6 Da; Peptide charge: 1+; monoisotopic/average: monoiso-
topic; Precursor m/z: none; Instrument: MALDI-TOF-TOF.
Statistics
The level of significance was in all statistical analyses set to
p,0.05. All results are expressed as mean 6 SEM.
Epo Receptor Expression in Skeletal Muscle
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Study A. Differences in western-blot analysis and insulin and
GH serum levels were detected using a two-way ANOVA followed
by Tukey’s multiple comparison tests, after checking for equal
variance. Data that were not normally distributed were log
transformed before analysis in order to pass normality test
(Shapiro-Wilk). IGF-I mRNA levels were analyzed by a paired
Student’s t-test, after checking for normality (Shapiro-Wilk). The
effect of Epo on SOCS3 mRNA content was tested by Wilcoxon
signed rank test, as the data was not normally distributed.
Study B. For detection of differences between the placebo
and rHuEpo treatment, a paired Student’s t-test was used, after
checking for normality (tested by Shapiro-Wilk). Data that did not
obtain normality were log transformed.
Study C. All intensity data were log transformed before
further analysis. The proteomics intensity data were tested for
normality (Shapiro-Wilk) and equal variance (t-test for
homogeneity of variance for two dependent samples), and if data
were normally distributed, the treatment effect was analyzed by a
paired Student’s t-test. Non-normally distributed data were
analyzed by Wilcoxon signed rank test.
SigmaPlot 11.0 was used for both statistical analysis and
graphical presentation in all studies.
Results
Skeletal muscle biopsies from 3 protocols were included: two
‘‘acute’’ studies (A and B), and one ‘‘prolonged study (C). Study A
included serial muscle biopsies 2–10 hours following a single i.v.
injection of rHuEpo (15.000 IU) or placebo in a non-fasting state.
Study B was included to provide a muscle biopsy in the fasting
state already 60 min after a single i.v. injection of rHuEpo using a
higher dose (,30.000 IU) or placebo. In study C the subjects were
treated with rHuEpo (5000 IU) s.c. every second day for 16 days,
and biopsies were collected at baseline and after the last injection.
Thus, study A and B were performed in order to elucidate the
acute and direct effects of rHuEpo treatment on Epo-R signalling,
while study C was used to screen for long-term effects of rHuEpo
treatment in skeletal muscle.
Plasma hormone levels
Insulin levels were significantly decreased at 4 h compared to
baseline in study A in both groups and at 10 h in the rHuEpo
group, reflecting a postprandial increase in insulin in response to
the breakfast served at baseline. Insulin levels were also
significantly increased at 10 h in the placebo compared to
rHuEpo group. In study B insulin levels were similar 4 h after
placebo as well as rHuEpo treatment. No significant difference in
plasma levels of GH was found in either study (Table 1).
Epo receptor
In study B, western blotting was performed with two different
antibodies against the Epo-R (C20 and M20). A band,
corresponding to the ,59 kDa Epo-R, was identified in all
samples and the positive control with the M20 antibody but not
with the C20 antibody. Figure 1 (A+B) shows the results for the
biopsy in the non-stimulated situation for all subjects compared to
the positive control (k-562 cells).
Furthermore, activation of the Epo-R by phosphorylation was
evaluated in both study A and B. Epo-R phosphorylation was
found to be unaffected by rHuEpo administration in both studies
(figure 1 C+D and figure 1).
Signal transduction pathways
Activation of the different signalling pathways related to the
Epo-R (and Epo-R phosphorylation, see above) was evaluated by
western blot analysis. Beta-actin was used as loading control. The
levels of b-actin protein were constant in all samples (data not
shown); therefore, the level of phosphorylation was normalized
only to the total level of the given protein. The membranes were
stripped, hence, the same membranes were incubated with first
phospho- then the total antibodies.
In study A, biopsies obtained before, 2 h, 4 h, and 6 h post
rHuEpo administration were analysed. No significant increases in
the phosphorylation of the activating sites on Lyn, STAT5, p38-
MAPK, IKK, or p70S6-kinase were found after rHuEpo
treatment relative to placebo (p.0.05). Akt phosphorylation was
high in the first muscle biopsy in both the rHuEpo and placebo
situation. This biopsy was obtained prior to rHuEpo/placebo
injection but after a breakfast meal (Figure 2). Subsequent to this,
the level of phosphorylation decreased after both rHuEpo and
placebo injections, even though the decline after 2 h was
significantly lower after rHuEpo as compared to placebo
(p = 0.014 Akt(ser473) and p= 0.032 Akt(thr308)) (Figure 2).
Overall, the observed pattern in Akt phosphorylation is most
likely a response to elevated insulin levels (Table 1) in response to
the breakfast served prior to the first biopsy, since insulin is known
to be a potent activator of Akt phosphorylation. Surprisingly,
MAPK phosphorylation was decreased at 4 and 6 hours post
rHuEpo (4 h; p = 0.046, 6 h; p = 0.003) (Figure 2). Furthermore,
sporadic increases in STAT5 phosphorylation were found. These
Table 1. Serum hormone levels.
Study A Placebo EPO Interaction
Pre 4 h post 10 h post Pre 4 h post 10 h post p-value
Insulin (pmol/l) 138.4641.2 34.8612.71* 106.5625.5** 128.7631.9 37.0613.81 76.2620.01 0.003
GH (ng/ml) 0.3360.05 3.6461.91 0.4260.10 2.4362.12 1.4461.11 0.3160.02 0.698
Study B Placebo EPO
4 h post 4 h post
Insulin (pmol/l) 30.865.3 39.269.1
GH (ng/ml) 2.4360.81 3.5561.48
1significantly different from pre (p,0.001).
*significantly different from 10 h post (p,0.001).
**significantly different from EPO 10 h post (p,0.001).
doi:10.1371/journal.pone.0031857.t001
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increases may be explained by sporadic peaks in serum GH, which
are known to induce activation of STAT5 in human muscle [23].
In study B, western blot analysis was performed on biopsies
obtained 1 hour after rHuEpo/placebo administration in the
fasting condition. Neither p-STAT5, p-MAPK, p-Akt, p-p70S6K,
p-IKK or p-LYN levels were significantly different between the
two treatments (p.0.05) (Figure 1).
mRNA levels of SOCS3 and IGF-I
All mRNA results were normalised to beta-actin levels. In study
B, mRNA levels were measured in the biopsies taken 1 h after
treatment. Because of limited amounts of muscle tissue, mRNA
levels were only measured in one biopsy 10 hours after rHuEpo
administration in study A. The levels of SOCS3 mRNA did not
change significantly either 1 h (study B) or 10 h (study A) post
treatment (p.0.05) (Figure 1 and 2). No significant changes in
IGF-I levels were found in biopsies obtained either 1 h (study B) or
10 h (study A) post treatment (p.0.05) (Figure 1 and 2).
Muscle proteome analysis
The proteome patterns for skeletal muscle tissue samples
obtained in study C showed marked homogeneity when resolved
by 2-DE. The pattern observed was conserved in each subject
before and after treatment with rHuEpo. The high molecular
weight region of the gel (.70 kDa) showed low resolution and
spots in this region were therefore not analysed. A total of 201
protein spots were identified in the skeletal muscle tissue of all
subjects (Figure 3).
Out of the 201 protein spots found in all the muscle samples, the
intensity of eight spots changed significantly after 16 days of
rHuEpo treatment. The intensity of two spots was increased, while
the remaining six spots displayed a decrease in spot intensity. The
two spots (A (p= 0.039) and B (p= 0.043)) that increased were
identified by MS and tandem MS as Myosin light chain 1 V/sB
(MLC1-V/sB) and a mixture of desmin and actin. Three of the
spots (C (p = 0.016), D (p= 0.023), and E (p= 0.001)) that
decreased were Creatine kinase M-type, and two spots (F
(p = 0.031) and G (p= 0.031)) Glyceraldehyd-3-phosphate dehy-
drogenase (GAPDH). The intensity of the last spot (H (p = 0.047))
was very low and the identity of this spot was therefore not
identified (Figure 4) (Table 2).
Discussion
This project was undertaken to study both acute and prolonged
effects of systemic rHuEpo exposure in human skeletal muscle in
vivo. Despite the presence of Epo-R protein by western blotting
functional activity in terms of pertinent signalling proteins was
absent after acute rHuEpo. By contrast, we did record unique
changes in muscle protein isoform expression with prolonged
treatment.
The Epo-R has previously been identified both on murine
myoblasts, murine primary satellite cells [12], rat myoblasts [24],
human myoblasts [24], and human skeletal muscle tissue [13,14].
Immunohistochemical staining has localized the Epo-R to the
sarcolemma [13,14]. Epo-R mRNA and Epo-R protein have also
been measured in muscle biopsies by PCR and western-blot
analysis, respectively. However, the specificity of the commercially
available Epo-R antibodies has been questioned [25,26], and there
is a need to develop new and more specific antibodies directed
against the Epo-R. In the current study, western blotting by two
different antibodies against the Epo-R was used to evaluate the
presence of the Epo-R. The M20 antibody recognized a band at
the level to where the Epo-R (,59 kDa) is predicted to migrate
both in the positive control and in all subjects. The band was
located slightly higher than the band found in the positive control.
This difference in molecular weight is most likely due to tissue
specific posttranslational modifications; the positive k-562 cells are
from a human leukaemia cell line in contrast to our human muscle
samples. However, the C20 antibody did not detect this band.
Thus, in support of the current literature [25,26] we conclude that
the C20 antibody is not able to identify the Epo-R in human
skeletal muscle. Even though the M20 antibody was able to detect
the ,59 kDa band, there is literature that recommends using this
antibody with caution until it has been thoroughly confirmed that
this band is the Epo-R [26]. Thus, further studies are needed to
confirm that this band is indeed the Epo-R.
In regard to Epo-R activation, in the current study we were not
able to detect phosphorylation of the Epo-R (Tyr456). We do
acknowledge that there are other phosphorylation sites on the
Epo-R, which has not been evaluated here due to lack of available
antibodies. In contradiction, Rundqvist et al. observed that
physical activity increased phosphorylation of Epo-R associated
JAK2 [14]. However, LeBaron et al. did not detect STAT5
activation after Epo stimulation to rat skeletal muscle tissue itself
[27]. In support of this, Hagstro¨m et al. showed only weak
amounts of Epo-R mRNA in mice skeletal muscle tissue, with no
up-regulation in response to hypoxia [28]. Furthermore, Rotter et
al. were not able to detect mRNA expression of Epo-R in rats
under basal conditions, whereas, a transient and unspecific
induction of the Epo-R gene expression was observed after
traumatisation of the muscle tissue [29]. Thus, it has to be further
established if the muscle tissue has to be stressed, by e.g. exercise
or traumatisation, in order to express and activate the Epo-R, as
shown by Rundqvist et al. [14] and Rotter et al. [29].
The presence and activation of the Epo-R in skeletal muscle
tissue can be questioned, even though the presence of the Epo-R
has been shown, the specificity of the antibodies used is debatable,
and studies regarding Epo-R mRNA expression and activation are
conflicting. It has to be established if the Epo-R is present on
skeletal muscle fiber cells or only on myoblasts and satellite cells.
Also, different levels of stress applied to the muscle tissue in
combination with rHuEpo administration need to be evaluated in
regard of Epo-R activation.
A number of different signalling molecules related to the Epo-R
were analysed in the current study, including Lyn, a docking
protein associated with the Epo-R in hematopoietic cells. Lyn has
been shown to induce tyrosine phosphorylation of the Epo-R at
levels comparable to JAK2 and to mediate activation of different
signalling pathways including STAT5 [18], PI3-kinase [19,30],
IKK [20], and raf-1/MAPK [31]. However, in the present study,
no change in the activation of either of the isoforms of Lyn was
Figure 1. Study B: Western blot and PCR results. A+B: Identification of the Epo-R in skeletal muscle tissue in the non-stimulated state in all 10
subjects with the C20 (A) and M20 (B) antibodies. Positive control is the k-562 cells. M is the molecular marker. C: Activation of the Epo-R by
phosphorylation evaluated by western blotting. The samples from the same subject in the stimulated and un-stimulated situation are loaded next to
each other D: Phosphorylation of Epo-R, STAT5, p38-MAPK, Akt, p70S6 kinase, Lyn, and IKK, all normalized to the levels of the given protein. The
mRNA levels of SOCS3 and IGF-I are normalized to beta-actin mRNA content. Black bars: placebo, white bars: rHuEpo. All results are from biopsies
taken 1 h post treatment with either placebo or rHuEpo.
doi:10.1371/journal.pone.0031857.g001
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found upon rHuEpo administration. Likewise, no increase in the
phosphorylation of STAT5, p70S6K, or MAPK was found. Akt
phosphorylation in study A was strongly affected due to a
postprandial increase in insulin, leading to high levels of Akt
phosphorylation before the treatment with rHuEpo. Thus, the
results regarding Akt in that study should be interpreted with
caution. Akt phosphorylation showed a decreasing pattern over
time, however this decrease was significantly attenuated 2 h after
rHuEpo treatment compared to placebo in study A. Should
rHuEpo stimulate Akt phosphorylation in human skeletal muscle,
an increase in Akt phosphorylation after 1 h in study B would have
been expected, thus, indicating that the difference seen in study A
is not due to changes in the Epo levels. Surprisingly, a significant
decrease in MAPK phosphorylation was observed 4 and 6 hours
post rHuEpo treatment. Currently we do not have an explanation
for this, but it could be indirect effects of the treatment that are
induced later. Furthermore, sporadic spikes in plasma GH were
observed in a few individuals, which occurred prior to transiently
increased pSTAT5 levels. This emphasizes the complexity of these
signalling pathways, and the importance of monitoring alternative
activators of a given pathway.
One explanation for the lack of activation could be that the dose
of Epo given in study A (,15 000 IU) was too low. The dose was
therefore increased to 400 IU/kg (,32.000) in study B, which
however, did not result in a detectable activation of the Epo-R.
These doses are comparable to the doses used to treat patients with
end-stage renal disease and stroke, respectively, and the highest
dose lead to a ,1000 fold increase in serum Epo levels. Previous
studies have shown that even minimal concentrations of Epo
activate STAT5, MEK, Ras, and ERKs in primary human
erythroid progenitors [32], thus, we would have expected to see an
activation of the signalling molecules analysed in the present
studies with the relatively high doses of rHuEpo used. From the
present study, however, we cannot rule out that even higher doses
of rHuEpo could have activated the Epo-R.
Along the same line, it also remains to be investigated if local
rather than systemic exposure to Epo would induce activation of
the Epo-R in human skeletal muscle in vivo. Local exposure would
also minimize the likelihood of systemic stimulation of other tissues
such as the bone marrow. This could be investigated by either in
situ microdialysis or local arterial perfusion. The latter approach,
however, is not well suited due to the long half-life of the hormone.
Microdialysis is a method that is particularly feasible for the
delivery of molecules with a small molecular size. Commercially
available microdialysis fibres have a cut-off value (,30 kDa) that is
too low to allow diffusion of rHuEpo (30.4 kDa). It is possible to
customize fibres with a higher cut-off value (3000 kDa), which
would allow diffusion of rHuEpo through the membrane. From a
theoretical point of view a more effective method would be
electrotransfer of the Epo gene into the skeletal muscle tissue,
however this method raises several ethical questions when used in
humans and are therefore not applicable.
Another potential explanation for the unaltered activation of the
analysed signalling pathways is that the biopsies were not taken at
the appropriate time-points after rHuEpo exposure. From cell
cultures it is known that Epo stimulation leads to phosphorylation
of STAT5, Akt, and ERK, which peaks after 15 min and remains
detectable after 60 min [33]. Probably the time for activation of
Figure 3. Representative 2D-gel. Representative 2D-gel of human skeletal muscle tissue. Protein spots that changed significantly (p,0.05) after
16 days of treatment with rHuEpo are shown and their identity given.
doi:10.1371/journal.pone.0031857.g003
Figure 2. Study A: Western blot and PCR results. Phosphorylation of STAT5, p38-MAPK, Akt, p70S6 kinase, Lyn, and IKK, all normalized to the
total levels of the given protein. Black bars: placebo, white bars: rHuEpo. The levels of mRNA are measured at 10 h post rHuEpo administration, and
are normalized to beta-actin mRNA levels. Level of significance p,0.05, * compared to baseline, # compared to control (same timepoint), 1
compared to rHuEpo 2 h. The interactions were as follows; pEpo-R p= 0.318, p38-MAPK p= 0.058 (treatment effect p = 0.030), pSTAT5 p=0.562, p-
Akt(ser) p = 0.001, pAkt(thr) p = 0.007, p-IKK p= 0.742 (time effect p = 0.017), p-LYN p=0.427, p-p70S6kinase p = 0.164 (time effect p = 0.033).
doi:10.1371/journal.pone.0031857.g002
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these pathways in vivo will be slightly prolonged, due to
transportation of the rHuEpo to the tissue of interest. It is possible
that the first biopsies in study A (2 h post) were taken after
maximal activation. Therefore, a biopsy was taken 1 h post
rHuEpo administration in study B, which however did not reveal
detectable phosphorylation of the pertinent signalling molecules.
Considering that Epo has a half-life between 2–13 h [34], an up-
regulation would have been expected within the time-points
analysed in the present studies.
To date, no studies have been able to document robust effects of
acute rHuEpo treatment in skeletal muscle. Thus, it remains a
question whether the Epo-R is biologically active in skeletal muscle
tissue. The results from the present study fits well with the mRNA
measurements (MRF4, VEGF, HIF-1a, IGF-IEa, ferroportin,
MyoD, myogen) performed by Lundby et al. on the same biopsies
as analysed in study A [13]. They were not able to find a
systematic regulation of a number of analysed mRNA molecules in
relation to rHuEpo treatment.
Epo does however seem to affect progenitor cells of the muscle
tissue (e.g. the satellite cells and myoblasts) [12,14,29]. Ogilvie et
al. found the Epo-R to be present on these cell types and that
stimulation by Epo mediates phosphorylation and thereby
activation of JAK2 and to a minor extent also STAT5 [12].
Stimulation led to increased cell proliferation and decreased
differentiation, which was accompanied by increased mRNA levels
of MyoD and Myf5 (markers of early and mid-myogenesis) and
decreased mRNA levels of myogenin (marker of irreversible
commitment to terminal differentiation). Furthermore, it was
Figure 4. Changes in muscle proteins; Desmin/Actin (A), Myosin light chain 1 V/sB (B), Creatin kinase M-type (C, D, E),
Glyceraldehyd-3-phosphat-dehydrogenase (F, G), and unidentified spot (H). I. Representative 3D image of spots showing intensity
changes between baseline and day 16. Images were obtained using the 3D viewer tool from PDQuest, which converts intensity to topographical
peaks. All spot images belong to the same subject. II. Mean changes in intensity for each spot. The difference between baseline and day 16 are
significant (p,0.05).
doi:10.1371/journal.pone.0031857.g004
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shown that Epo increased the proliferation of satellite cells
significantly more than placebo during the first 14 days upon
muscle trauma [29]. This suggests a role for Epo in maintaining or
expanding the pool of proliferating muscle progenitor cells during
differentiation. This theory was partly supported by previously
published results from study A, where MRF4 mRNA was
transiently up-regulated 6 h after rHuEpo administration, whereas
other markers of satellite cell differentiation (MyoD and myogenin)
were unaltered [13]. These analyses were performed on muscle
biopsies in which the abundance of satellite cells is low, which
might have masked any effects of rHuEpo on these progenitor
cells.
In the present study proteomic analysis was used to investigate
how muscle tissue responds to prolonged treatment with rHuEpo.
All the identified proteins have previously been detected in both
slow and fast muscle fibres [35]. The intensity of two spots (protein
isoforms) was found to be significantly up-regulated 16 days after
rHuEpo administration. One spot was identified as an isoform of
myosin light chain 1 V/sB (MLC1-V/sB), by MS and MS/MS
analysis. The other spot corresponded to a combination of
isoforms of desmin and actin. It should be emphasized that the
spots, that were upregulated, belong to a train of spots (or protein
isoforms), and that in the present study only one of these isoforms
was significantly changed. Theoretically, these trains of spots could
contain entirely different proteins with similar molecular weight
and varying isoelectric points. However, each spot in a train often
represents different isoforms of the same protein carrying different
post-translational modifications. In the current study it was not
possible by MS or MS/MS analysis to distinguish between these
isoforms. The effect of Epo on myosin light chain, have been
investigated by Cayla et al in rats [17]. They found that Epo
treatment increases the relative amount of the slow myosin light
chain (MLC) isoforms but decreases the amount of fast MLC
isoforms. This change from a fast phenotype to a slower one
resembles the changes seen in relation to endurance training [36].
In support of this hypothesis, proteomic analyses of slow versus fast
muscle fibres showed that the slow fibres had a significant larger
amount of MLC1-V/sB [35]. In the current study, MLC1-V/sB,
which is the most abundant slow alkali isoform found in human
muscle tissue [36], was increased which supports the findings by
Cayla et al [17]. In humans, 14 weeks of rHuEpo treatment did
not induce any changes in the number or size of the muscle fibres,
indicating that rHuEpo does not have anabolic effects on skeletal
muscle tissue [13]. Thus, further studies with longer treatment (.2
weeks) of human subjects with rHuEpo is needed to in order to
clarify if rHuEpo can induce a shift from a fast glycolytic to a slow
oxidative phenotype.
One spot containing desmin and actin was also significantly up
regulated. Actin is a major structural protein in muscle tissue,
which in combination with myosin is critical for muscle
contraction. Desmin strengthens the fibrous network and connects
myofibrils to each other and to the plasma membrane. The effects
of Epo on these proteins in skeletal muscle are currently unknown.
The intensity of the remaining 6 spots all decreased significantly
at day 16, of which the identity of one remains unidentified. Three
spots were identified as creatine kinase M-type (CK) and the
remaining 2 spots as isoforms of glyceraldehyd-3-phosphate
dehydrogenase (GAPDH). Both of these proteins are involved in
the re-synthesis of ATP. Creatine kinase reversibly catalyses the
transfer of phosphate between ATP and various phosphogenes,
and GAPDH is one of the enzymes involved in glycolysis and
thereby in the breakdown of glucose for energy. Thus, these results
could indicate that rHuEpo exerts inhibitory effects on fast
generation of ATP in skeletal muscle tissue. In support of this,
proteomic analyses of skeletal muscle have shown that the levels of
CK and GAPDH are higher in fast muscle fibres compared to
slow fibres [35]. It has previously been shown in rats, that Epo
alone, without training, can induce a shift from a fast glycolytic to
a slow oxidative phenotype. Epo induced a significant increase in
the activity of the oxidative enzymes cytochrome c oxidase, L-3-
hydroxyacyl CoA dehydrogenase and citrate synthase, however,
phosphofructokinase also increased [17]. Furthermore, over-
expression of Epo in mice skeletal muscle tissue lead to up-
regulation of genes involved in lipid metabolism while genes
involved in glucose metabolism were down-regulated [37]. In
contrast, 13 weeks of treatment with rHuEpo in humans did not
lead to changes in levels of either hexokinase or cytochrome c [16].
In summary, the current study supports previous findings
indicating that rHuEpo treatment can lead to changes in structural
proteins and various metabolic enzymes. If this ultimately leads to
Table 2. Mass spectrometry identity matches for significant spots.
Spot # Protein Uniprot # MS results MS/MS results
Matched
fragments
Sequence
coverage (%)
Score
(mascot)
Matched
fragments
Sequence
coverage (%)
Score
(mascot)
A Desmin P17661 9/36 27 72 4/49 14 256
Actin (unspecific) 5/36 17 37 2/49 7 159
B Myosin light chain 1 V/sB P05976 5/22 29 73 3/34 14 240
C Creatine kinase M-type P06732 9/18 38 121 7/29 28 338
D Creatine kinase M-type P06732 12/35 41 156 8/48 33 649
E Creatine kinase M-type P06732 15/39 49 182 7/52 33 618
F Glyceraldehyd-3-phosphate
dehydrogenase
P04406 - - - 1/36 4 59
G Glyceraldehyd-3-phosphate
dehydrogenase
P04406 - - - 2/16 8 129
H ?? - - - - - - -
Matched fragments; the number of peptides matched with the protein/the total amount of peptides in the sample. Sequence coverage; the percentage of the total
protein that the matched peptides cover. Score; the score given by MASCOT, for MS results a score above 66 (56 for actin) was considered significant (p = 0.05), for MS/
MS the significance level was a score of 34–37 (protein dependent). Mascot: http://www.matrixscience.com. Uniprot: http://www.uniprot.org.
doi:10.1371/journal.pone.0031857.t002
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a shift in skeletal muscle phenotype from a fast to a slower one, still
needs to be determined.
Conclusion
The presence of the Epo-R in human skeletal muscle tissue was
verified in the current study only by the M20 antibody, but we
were unable to detect rHuEpo-mediated activation of the Epo-R
or downstream signalling proteins in the resting condition. In
contrast, by using a proteomic approach we observed changes in
several isoforms of different proteins in muscle after more
prolonged rHuEpo administration in a pattern compatible with
increased oxidative capacity. These latter effects are likely to be
indirect.
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